EMA Authorised: Amyvid (florbetapir (18F)) — Eli Lilly Nederland B.V.

View source ↗

Summary

The European Medicines Agency authorised Amyvid (florbetapir (18F)) for radionuclide imaging. The marketing authorization holder is Eli Lilly Nederland B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• AMYVID (Florbetapir F-18)

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging. MAH: Eli Lilly Nederland B.V.. Decision date: 16/01/2026